Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis

被引：0
|
作者：
David N. Adam
Marie Y. Jablonski Bernasconi
Henrik Thoning
Jashin J. Wu
机构：
[1] University of Toronto,Division of Dermatology, Temerty Department of Medicine
[2] CCA Medical Research,Department of Dermatology
[3] Probity Medical Research,undefined
[4] Leo Pharma,undefined
[5] University of Miami Miller School of Medicine,undefined
来源：
Dermatology and Therapy | 2022年 / 12卷
关键词：
Betamethasone dipropionate; Calcipotriol; Foam; Halobetasol propionate; Psoriasis; Tazarotene;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2589 / 2600
页数：11
相关论文
共 37 条
  • [31] Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. J Med Econ. 2020;23(6):641-649
    Glick, Brad
    Guerin, Annie
    Ayyagari, Rajeev
    Lin, Tina
    Jacobson, Abby
    Joseph, George
    Kircik, Leon
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1499 - 1500
  • [32] Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
    Kim Rand
    Juan Manuel Ramos-Goñi
    Bülent Akmaz
    Laia Solé-Feu
    José-Carlos Armario-Hita
    Dermatology and Therapy, 2024, 14 (1) : 183 - 185
  • [33] Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data
    Istvan Majer
    Gijs van de Wetering
    Zoltan Polanyi
    Arun Krishna
    Elisabeth Gray
    Anuja Roy
    Applied Health Economics and Health Policy, 2017, 15 : 45 - 55
  • [34] Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data
    Majer, Istvan
    de Wetering, Gijs van
    Polanyi, Zoltan
    Krishna, Arun
    Gray, Elisabeth
    Roy, Anuja
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (01) : 45 - 55
  • [35] A 1-year, randomized, double-blind safety study of long-term treatment of a new gel formulation containing calcipotriene plus betamethasone dipropionate in scalp psoriasis
    Luger, Thomas
    Kidson, Paul
    Cambazard, Francois
    Larsen, Frederik Gronhoj
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB134 - AB134
  • [36] Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'
    Bastian, Mike
    Freemantle, Nick
    Rossi, Ana B.
    Shumel, Brad
    Le Bagousse, Gaelle Bego
    Wang, Zhixiao
    Xu, Yingxin
    Guyot, Patricia
    DERMATOLOGY AND THERAPY, 2024, 14 (03) : 819 - 821
  • [37] Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study
    Ochs-Ross, Rachel
    Wajs, Ewa
    Daly, EllaJ.
    Zhang, Yun
    Lane, Rosanne
    Lim, Pilar
    Drevets, Wayne C.
    Steffens, David C.
    Sanacora, Gerard
    Jamieson, Carol
    Hough, David
    Manji, Husseini
    Singh, Jaskaran B.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2022, 30 (05): : 541 - 556
1234